Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Quick facts
Marketed products
- Meropenem-Vaborbactam · Infectious Disease
Meropenem-vaborbactam is a carbapenem antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the carbapenem from enzymatic degradation.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) portfolio CI brief
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) pipeline updates RSS
Frequently asked questions about Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
What are Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)'s marketed drugs?
Top marketed products include Meropenem-Vaborbactam.
Related
- Meropenem-Vaborbactam · Infectious Disease
- Sector hub: All tracked pharma companies